Oxaphosphinanes: New Therapeutic Perspectives for Glioblastoma
- 14 February 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (5), 2196-2211
- https://doi.org/10.1021/jm201428a
Abstract
This paper reports the design and the synthesis of a new family of compounds, the phostines, belonging to the [1,2]oxaphosphinane family. Twenty-six compounds have been screened for their antiproliferative activity against a large panel of NCI cancer cell lines. Because of its easy synthesis and low EC50 value (500 nM against the C6 rat glioma cell line), compound 3.1a was selected for further biological study. Moreover, the specific biological effect of 3.1a on the glioblastoma phylogenetic cluster from the NCI is dependent on its stereochemistry. Within that cluster, 3.1a has a higher antiproliferative activity than Temozolomide and is more potent than paclitaxel for the SF295 and SNB75 cell lines. In constrast with paclitaxel and vincristine, 3.1a is devoid of astrocyte toxicity. The original activity spectrum of 3.1a on the NCI cancer cell line panel allows the development of this family for use in association with existing drugs, opening new therapeutic perspectives.Keywords
This publication has 34 references indexed in Scilit:
- Revisited Synthesis of Aryl-H-phosphinatesSynthesis, 2011
- Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapyJournal of Neuro-Oncology, 2011
- Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade GliomaJournal of Clinical Oncology, 2010
- Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant GliomaCA: A Cancer Journal for Clinicians, 2010
- Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004Neuro-Oncology, 2010
- Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trialThe Lancet Oncology, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- A gene expression database for the molecular pharmacology of cancerNature Genetics, 2000
- Systematic variation in gene expression patterns in human cancer cell linesNature Genetics, 2000
- Adenovirus-mediated suicide gene therapy in an in vitro model of reactive gliosisGlia, 1999